New funding

New funding

WaveTec VisionR, which recently introduced the ORA System™, a diagnostic device that brings revolutionary precision to cataract surgery, has recently closed a new round of financing, securing an additional $16.5m. This latest round was led by a new investor, Burrill & Company. All of the company’s previous investors also participated in this round of financing, including Versant Ventures, Accuitive Medical Ventures, De Novo Ventures and Gund Investment Corporation “The participation of a new lead investor further validates the scientific and clinical potential of the ORA System,†said Tom Frinzi, WaveTec president and CEO. “This new capital enables us to further expand our commercial efforts as well as continue product refinement,†he said.

www.wavetecvision.com

Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...